Clinical Challenges: Managing Pediatric Crohn’s Disease
Pediatric Crohn’s disease (CD) is on the rise, with an estimated 40,000 U.S. children affected by this potentially growth-stunting condition. This increase is not an artifact of better detection. “Rather, it appears that Western diets, antibiotic exposure early in life, and dietary emulsifiers may contribute to disease pathogenesis,” said Jeffrey Hyams, MD, of Connecticut Children’s […]
Explanations Don’t Help Clinicians Spot Biased AI
Providing clinicians with artificial intelligence (AI) predictions along with model explanations can boost diagnostic accuracy, but that accuracy drops when using a biased AI model — and explanations don’t mitigate those negative effects, according to a randomized clinical vignette survey study. Clinicians who were asked to differentiate between pneumonia, heart failure, or chronic obstructive pulmonary […]
Dr. Barbie Will See You Now, but Only If You’re a Pediatric Patient
Barbie can be a doctor, but she rarely specializes or works with adults, and she almost never meets clinical safety standards for clothing or personal protective equipment (PPE), a quantitative study found. Of 80 Barbie medical professional dolls, 53 (66%) worked with children as a pediatrician, pediatric dentist, or even a pediatric ophthalmologist, Katherine Klamer, […]
Clinical Challenges: Using Pola-R-CHP for Diffuse Large B-Cell Lymphoma
Earlier this year, the FDA approved a new frontline option for patients with diffuse large B-cell lymphoma (DLBCL): the antibody-drug conjugate polatuzumab vedotin (Polivy) in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP). Combination chemotherapy involving rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) — and before that, CHOP alone — has been the established option […]
Red Meat Consumption Tied to Higher Chance of UC Flare
ORLANDO – For people with inflammatory bowel disease (IBD), that hamburger may come with more than just a side of fries — red meat consumption was linked with a higher risk for ulcerative colitis (UC) flare, researchers reported. According to an analysis of data from the IBD Partners research, patients with UC who were in […]
National Database Study Finds Higher Risk for Barrett’s Esophagus in IBD
ORLANDO – People with inflammatory bowel disease (IBD) faced higher odds of Barrett’s esophagus (BE) and BE without dysplasia, but not BE-linked malignancy, according to a cross-sectional study. Among patients diagnosed with ulcerative colitis (UC), the prevalence of BE was 0.077%, while the prevalence of BE in patients with Crohn’s disease (CD) came in at […]
FDA Approves New First-Line Standard of Care in Bladder Cancer
Patients with locally advanced or metastatic bladder cancer have a permanent new first-line standard of care after the FDA granted full approval to the combination of enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) regardless of cisplatin eligibility. The action finalized the approval process for the combination, which received accelerated approval earlier this year, at the time […]
JAK1 Inhibitor Shows ‘Remarkable’ Activity in T-Cell Lymphoma
Treatment with a novel, oral JAK1 tyrosine kinase inhibitor induced rapid and durable responses in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), findings from a single-arm phase II study showed. Among 88 heavily pretreated patients evaluable for efficacy, 44% (95% CI 34-55) responded to single-agent golidocitinib, with 24% (95% CI 15-34) achieving a […]
Low-Dose Intradermal Mpox Vaccine on Par With Subcutaneous Dosing
Mpox vaccination with a two-shot, low-dose intradermal approach produced similar antibody titers levels compared with the standard subcutaneous dosing regimen, an observational study showed. Two 0.1-mL intradermal doses of the modified vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine yielded geometric mean titers of immunoglobulin G (IgG) antibodies that neutralize mpox of 88.65 (95% CI 48.09-163.42), compared with […]
Very Early ART Can Result in Sustained HIV Suppression in Neonates
In neonates with acquired in utero HIV infection, administration of antiretroviral therapy (ART) within 48 hours of life can lead to sustained HIV virological suppression by 2 years, a phase I/II proof-of-concept study indicated. In two cohorts who received three-drug nevirapine-based ART regimens within two days of life and maintained protocol- defined virological control criteria […]